Bellevue Group’s Kite Pharma, Inc. KITE Stock Holding History

Bellevue Group’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-17,000	Closed	-$1.76M	–	134
2017 Q2	$1.76M	Buy	17,000 +3,000	+21%	+$245K	0.21%	84
2017 Q1	$1.1M	Hold	14,000	–	–	0.15%	100
2016 Q4	$628K	Hold	14,000	–	–	0.13%	105
2016 Q3	$782K	Hold	14,000	–	–	0.14%	105
2016 Q2	$700K	Hold	14,000	–	–	0.13%	106
2016 Q1	$643K	Buy	+14,000	New	+$678K	0.12%	105

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bellevue Group's KITE Position: Q3 2017 in Review

Bellevue Group sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 17,000 shares — an estimated $1.76M sold.

Bellevue Group first reported a position in KITE in Q1 2016 and held it in 6 quarters. The position peaked at $1.76M in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

Bellevue Group reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
Bellevue Group sold 17,000 Kite Pharma, Inc. shares in Q3 2017, an estimated $1.76M.
Bellevue Group first reported a position in Kite Pharma, Inc. in Q1 2016 and held it in 6 quarters.
Bellevue Group's Kite Pharma, Inc. position peaked at $1.76M in Q2 2017.
244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Bellevue Group's 13F filing for Q3 2017, filed 13 Nov 2017.